GET DAILY SIGNALSCoherus Oncology (CHRS): Analyst Targets Point to +845% Upside Potential
Key Takeaways
- The central stock price target of $7.75 represents the arithmetic mean of verified analyst targets, drawn from roughly six analysts currently covering the name.
- With CHRS recently trading near $0.82, that target implies upside of roughly 845% — a substantial move by any measure.
- Individual analyst targets range widely from about $4.00 to $10.00, with a few older figures near $12.00, highlighting significant disagreement on the oncology pipeline outlook.
- Support for a higher valuation rests mainly on the approved LOQTORZI product and upcoming clinical readouts, while risks center on ongoing losses, cash burn, dilution, and Nasdaq listing compliance.
- Coherus has divested its biosimilars business, reduced debt by more than 90%, and repositioned as a pure-play cancer immunotherapy company.
- The stock trades below $1.00 and carries a Nasdaq minimum-bid-price deficiency notice, adding structural pressure beyond fundamentals.
- For more detail on this ticker's Major News, Today's Price Move, Forecast, and Earnings, explore these dedicated pages for updated analysis and data.
- To see how automated AI models are currently reading this and other tickers, explore Trending AI Robots.
Understanding the Analyst Price Targets
Coherus Oncology (CHRS) — formerly Coherus BioSciences — is a commercial-stage biopharmaceutical company focused on immunotherapies for cancer. Coverage remains relatively thin, and the analyst price target range is unusually wide. Aggregating recent, verifiable targets shows estimates spanning roughly $4.00 to $10.00, with a handful of older figures near $12.00. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent views include a Buy rating with a $7.00 target from H.C. Wainwright and a Buy rating with a $7.00 target from Maxim Group, while Guggenheim has kept a Buy while adjusting its target into the $8.00 to $10.00 range. UBS has maintained a Hold with a much lower, older target near $1.10, illustrating how divided opinions remain. The calculated mean of these verified targets comes to approximately $7.75, the rounded central target used here — not an official published consensus. The dispersion largely reflects differing assessments of pipeline success probabilities and the financing path ahead rather than a unified valuation view.
Current Market Position and Path to the Target
At a recent share price near $0.82, reaching the $7.75 target would require a move of roughly 845%. Coherus sold its UDENYCA biosimilar franchise, rebranded as a pure oncology company, and cut secured and convertible debt by more than 90%. That transition left a smaller revenue base, however. Trailing twelve-month revenue sits around $51 million, with trailing twelve-month EBITDA near negative $148 million and EPS near negative $1.25. Cash and investments stood at about $105 million as of the most recent quarter, and management has guided LOQTORZI revenue to roughly $57–62 million for 2026. A path to the target would likely require successful clinical data, meaningful revenue growth, and either favorable new financing or a strategic transaction.
Factors That Could Support a Move Higher
- Approved, growing product: LOQTORZI (toripalimab) is FDA-approved for recurrent or metastatic nasopharyngeal carcinoma, with management targeting sequential quarterly growth of 10–15%.
- Clinical catalysts: Enrollment has completed in multiple studies, including casdozokitug (CADILYZE) in first-line liver cancer and TAGMO cohorts in head and neck and colorectal cancers, with data readouts expected through 2026–2027.
- Leaner cost structure: SG&A expenses have declined for six consecutive quarters, and the divestiture sharply reduced leverage.
- Pipeline valuation: Bulls argue the stock prices in little value for the pipeline, leaving room for re-rating if any program succeeds.
Risks That Could Keep the Target Out of Reach
- Cash burn and dilution: Cash declined from about $167 million to $105 million in a single quarter, and an at-the-market offering program with material remaining capacity creates ongoing dilution risk.
- Nasdaq compliance: The stock has traded below $1.00, triggering a minimum-bid-price deficiency notice and raising the possibility of delisting or a reverse split.
- Clinical risk: Early-stage oncology data is inherently uncertain, and a negative or ambiguous readout could sharply reset expectations.
- Profitability: With negative EBITDA and a shrinking legacy revenue base, the business is not yet self-funding.
Technical Levels and Market Structure
The 52-week range is roughly $0.70 to $2.62, and the stock has spent extended periods below the psychologically significant $1.00 level. Because the resistance level at $1.00 now carries added weight as a Nasdaq compliance threshold, regaining and holding that level is likely to be a necessary first step before any move toward higher targets. There is no meaningful nearby support level besides the recent lows near the bottom of the 52-week range, and the long-term trend remains decisively lower.
Time Horizon and Items to Monitor
Analyst price targets typically reflect a research horizon of about 12 months, though the exact horizon varies by firm. Given the implied move is so large, investors should treat the target as a multi-year, event-driven scenario rather than a near-term expectation. Key items to monitor include quarterly LOQTORZI revenue and cash balances, clinical data readouts for casdozokitug and TAGMO, any financing or dilution announcements, analyst rating or target revisions, and resolution of the Nasdaq listing status.
How I Incorporate Tickeron’s AI Daily Buy/Sell Signals
In my own workflow I often turn to Tickeron’s AI Daily Buy/Sell Signals to monitor shifting momentum on names like this. The tool applies artificial intelligence across thousands of stocks and ETFs to generate Buy, Sell, or Hold signals based on technical behavior and market conditions. For a volatile, event-driven stock, it helps surface inflection points more efficiently than manual review alone, allowing me to cross-check my fundamental view against real-time AI-driven trends before making any decisions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
CHRS's Stochastic Oscillator sits in oversold zone for 6 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CHRS's RSI Indicator exited the oversold zone, 29 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
Following a +9.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where CHRS advanced for three days, in 182 of 239 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
CHRS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CHRS as a result. In 75 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for CHRS turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 44 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CHRS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CHRS entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.955) is normal, around the industry mean (3.498). P/E Ratio (-0.733) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.240) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (3.149) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. CHRS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CHRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of biologic therapeutics for oncology and inflammatory diseases
Industry Biotechnology
Advertisement